Skip to main content

Professor Kevin Winthrop, MD, MPH

Professor Kevin Winthrop, MD, MPH

Professor of Infectious Diseases, Ophthalmology,
Professor of Public Health and Preventive Medicine (joint appointment),
Division of Infectious Diseases, OHSU
Oregon Health and Sciences University
Portland, Oregon, USA

Related Videos

What are the non-negotiable features, symptoms, test results, and findings that confirm the diagnosis of NCFBE and, by extension, therefore make persons potential candidates for inflammation-targeting therapy with such drugs as brensocatib?

What are the non-negotiable features, symptoms, test results, and findings that confirm the diagnosis of NCFBE and, by extension, therefore make persons potential candidates for inflammation-targeting therapy with such drugs as brensocatib?

How are brenscocatib and other investigational drugs in the pipeline shaping/changing the multimodal treatment landscape for NCFBE?

How are brenscocatib and other investigational drugs in the pipeline shaping/changing the multimodal treatment landscape for NCFBE?

What are the non-negotiable features, symptoms, test results, and findings that confirm the diagnosis of NCFBE and therefore make persons potential candidates for inflammation-targeting therapy with such drugs as brensocatib?

What are the non-negotiable features, symptoms, test results, and findings that confirm the diagnosis of NCFBE and therefore make persons potential candidates for inflammation-targeting therapy with such drugs as brensocatib?

Even with the introduction of new inflammation-reducing agents such as brensocatib, what do you envision will be the role of antibiotics as a mainstay in the NCFBE toolkit?

Even with the introduction of new inflammation-reducing agents such as brensocatib, what do you envision will be the role of antibiotics as a mainstay in the NCFBE toolkit?

Professor Winthrop, can you kindly introduce yourself and share with us your role at Oregon Health Sciences University? And what you plan to cover in this landmark iQ&A Bronchiectasis Pulmonary Medicine Intelligence Zone?

Professor Winthrop, can you kindly introduce yourself and share with us your role at Oregon Health Sciences University? And what you plan to cover in this landmark iQ&A Bronchiectasis Pulmonary Medicine Intelligence Zone?

Can you explain the importance of neutrophil-mediated inflammation as a driver of the pathobiology of NCFBE, and the implications of approaches that mitigate the effects of this progressive process across the heterogeneous spectrum?

Can you explain the importance of neutrophil-mediated inflammation as a driver of the pathobiology of NCFBE, and the implications of approaches that mitigate the effects of this progressive process across the heterogeneous spectrum?

Which elements of the ASPEN and WILLOW trial designs best help clinicians identify NCFBE patients likely to benefit from brensocatib and offer an evidence-based framework for monitoring them during treatment?

Which elements of the ASPEN and WILLOW trial designs best help clinicians identify NCFBE patients likely to benefit from brensocatib and offer an evidence-based framework for monitoring them during treatment?

Can you discuss the current burden of NCFBE and the unmet need for the healthcare system? How do we address high disease burden, increasing prevalence, and profoundly impaired quality of life in NCFBE?

Can you discuss the current burden of NCFBE and the unmet need for the healthcare system? How do we address high disease burden, increasing prevalence, and profoundly impaired quality of life in NCFBE?

Given the statistically significant improved FEV1 outcomes in of the 25mg vs 10mg dose of brensocatib, and virtually equivalent side effect profiles of the two dosing regimens, how do you use the data to guide your use, dose-wise, of brensocatib?

Given the statistically significant improved FEV1 outcomes in of the 25mg vs 10mg dose of brensocatib, and virtually equivalent side effect profiles of the two dosing regimens, how do you use the data to guide your use, dose-wise, of brensocatib?